Important question, the second one. As for your first, I said the Phase 2A results were "not bad" (with a thorough explanation of exactly what I meant vs "good" or "great"), and that the Phase 2A did not prove any efficacy by a long shot and that the Part B results would have to be - and had the potential to be - much more telling.
And the market generally feels the same I think. Unlike the general market, I did not sell because I'm still very supportive of 2-73 and I invested in the company, not the daily share price. I can wait for the Part B.
Yep I've been reading that 2-73 agonizes both the S1 and M1 (and perhaps other muscarinics) receptors together in a very particular way. More specifically: in some manner(s) that alleviate the particular pathologies the company is targeting. This is perhaps what separates it from other S1 agonists. No one knows specifically, though Maurice et al have their theories on the general actions. It should be noted: there are many approved medicines whose MOA is not fully understood. 2-73 can be proven useful without that complete fundamental understanding. The FDA does not make that an approval requirement.
News 
Market Data 
Discover 
AI
